Re Agreement

RNS Number:1181T
Profile Therapeutics PLC
11 December 2003


Immediate Release                                              11 December 2003



                            Profile Therapeutics plc

               Intelligent inhaler agreement with Schering France


Profile Therapeutics plc ("Profile"), which develops and commercialises
specialist inhaled therapies, is delighted to announce that it has agreed to
supply Schering S.A. ("Schering France") with its Prodose intelligent inhalers
to support Schering's product Ventavis(R), their recently-approved medicine for
Primary Pulmonary Hypertension.

This is the second Schering subsidiary that will launch Ventavis to its patients
in conjunction with Prodose. In October Profile announced that it had agreed a
supply and services agreement with Schering Healthcare Ltd for the UK, another
key European market.  Profile is supplying an initial order of over 60 devices
to Schering France and will receive an annual fee for each patient.

Primary Pulmonary Hypertension is a rare lung disorder in which the blood
pressure in the pulmonary artery rises far above normal levels for no apparent
reason1.  There are around 100 patients in France and approximately 2,000 across
Europe.  Profile is continuing to discuss with Schering AG how it can support
Ventavis in other European markets.

Commenting on today's announcement, John Lisle, Chief Executive of Profile,
said:

"I am very pleased that Schering S.A., France has become the second market to
adopt Prodose for their Ventavis patients.  It is great news for patients as it
gives them a state-of-the-art delivery system to help improve the effectiveness
of their treatment and their quality of life.  The agreement further underlines
the value of the Prodose intelligent inhaler, which we first launched in
November 2002."


                                    - ENDS -



1 Primary Pulmonary Hypertension: division of lung diseases and office of
prevention, education and control.  US department of Health and Human Services.
Public Health Service. National Institutes of Health.  National Heart, Lung and
Blood Institute.  NIH Publication No. 96-3291, Revised November 1996.



For further information, please contact:

Profile Therapeutics
John Lisle, Chief Executive Officer                           Tel: [phone]
Simon McGuire, Sales & Marketing Director

Buchanan Communications                                       Tel: [phone]
Tim Anderson
James Strong



Notes to Editors:

Profile Therapeutics plc develops and commercialises specialist inhaled
therapies to improve the treatment of respiratory patients. Profile's core
patient groups are the young, the elderly and individuals with severe
respiratory impairment.  The diseases targeted by Profile include: cystic
fibrosis, primary pulmonary hypertension, asthma, emphysema, chronic bronchitis,
sleep disorders and Chronic Obstructive Pulmonary Disease ("COPD").

Profile has developed proprietary innovative delivery systems using its "
intelligent inhaler" technology known as Adaptive Aerosol Delivery or AAD(R).
These systems automatically respond to individual patients' breathing patterns
to deliver a precise dose and have been shown under long-term clinical trials to
significantly enhance patient compliance to therapy.

Profile's first drug PromixinTM, an inhaled antibiotic for cystic fibrosis
patients, was launched in the UK in March 2003.  Schering's Ventavis(R) is the
second medicine to be delivered using the Prodose.   Profile recently announced
an agreement to supply CoTherix Inc with Prodose intelligent inhalers to develop
an inhaled Iloprost product for the US market.  Profile has also formed a joint
venture with Breath Ltd. to develop a range of respiratory medicines for the US
market with the Prodose HandHeld, which is currently in development for launch
in 2004.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRNKKKDOBDDCBD